Last Updated on February 23, 2024 by The Health Master
Brand Names
In a recent development, the National Human Rights Commission (NHRC) has directed its attention towards the pharmaceutical landscape in India, raising concerns over the confusingly similar brand names of various drugs.
The NHRC, having taken suo motu cognisance of a newspaper article, has sent notices to the Union Health Ministry and the Drugs Controller General of India, signaling the gravity of the issue.
Understanding the Allegations
1. Identical Brand Names, Different Ailments
The NHRC has expressed distress over a revelation that numerous drugs with identical or phonetically similar names are being prescribed for distinct medical conditions.
This creates a potential hazard for patients, as pharmacists may dispense the wrong medication due to the confusion surrounding these names.
2. The Absence of a Comprehensive Database
The Central Drugs Standard Control Organisation (CDSCO) is reported to lack a comprehensive database of all pharmaceutical brand names.
This lack of centralized information poses a significant challenge in addressing the issue effectively.
3. Prescription Errors and Accountability
The NHRC points out a critical aspect – the absence of data on prescription errors maintained by the authorities.
This raises questions about accountability in the pharmaceutical realm, where precision is paramount.
The Commission’s Stance
4. Serious Human Rights Implications
If the claims in the newspaper article hold true, the NHRC asserts that the situation amounts to a “serious issue of human rights.”
The potential consequences of administering the wrong medication due to confusing brand names underscore the gravity of the matter.
5. Notices Issued to Key Authorities
In response to the alarming scenario painted by the media article, the NHRC has issued notices to the secretary, Union Ministry of Health & Family Welfare, and the Drugs Controller General of India.
They have sought a detailed report within four weeks, encompassing steps taken or proposed to address the identified problem.
6. Lack of Prescription Error Data
The NHRC’s concern extends to the lack of data on prescription errors, emphasizing the need for accountability and a robust system to track and rectify such errors promptly.
Concrete Examples of the Issue
7. Linamac 5 vs. Linamac: A Cancerous Confusion
The newspaper article cites examples like ‘Linamac 5,’ prescribed for multiple myeloma (a type of cancer), and another drug named ‘Linamac,’ which is intended for diabetes treatment.
Such instances highlight the potential harm arising from ambiguous drug names.
8. Medzole’s Multiple Identities
‘Medzole’ is identified as a brand name used by different companies to sell drugs with entirely different active ingredients.
The confusion extends to medications treating conditions ranging from sedation and stomach acidity to deworming treatment for children and powerful antifungal drugs.
9. Similar Trade Names, Different Functions
The article also unveils the use of similar trade names that are both phonetically and visually alike.
For instance, ‘Medpol’ sells paracetamol, ‘Medrol’ offers a corticosteroid, and ‘Metrozole’ markets an antibiotic.
The subtle variations in these names pose a risk of confusion for both healthcare providers and patients.
NHRC’s Call to Action
10. Database Building by CDSCO
To tackle the issue at its root, the NHRC suggests that the CDSCO should initiate the construction of a comprehensive database.
This database would consolidate information from the Drug Controllers in each state and Union Territory, facilitating better regulation of pharmaceutical brand names.
11. Accountability and Reporting
The NHRC’s notices to key authorities emphasize the need for a detailed report within four weeks.
This report should outline the steps taken or proposed to rectify the issue, ensuring accountability in the pharmaceutical sector.
12. Consequences of Confusion
Highlighting the potential consequences of confusion in drug prescriptions, the NHRC underscores the gravity of the situation.
The Commission is keen on understanding the measures being taken to address the identified challenges and safeguard patients’ well-being.
The Way Forward
13. Enhancing Prescription Clarity
As the NHRC delves into the matter, it prompts a broader conversation on enhancing prescription clarity.
The pharmaceutical industry may need to reevaluate naming conventions to reduce the likelihood of confusion and mitigate potential risks to patient safety.
14. Strengthening Regulatory Measures
The NHRC’s intervention brings to light the need for stronger regulatory measures in the pharmaceutical sector.
A proactive approach to streamline brand names and ensure precision in prescription can prevent inadvertent errors and safeguard public health.
15. Public Awareness and Vigilance
In conclusion, the NHRC’s scrutiny underscores the importance of public awareness regarding drug names and potential confusion.
Patients and healthcare providers must remain vigilant to mitigate risks associated with similar-sounding medications.
Disclaimer: This article contains information derived from the source mentioned below. Our team utilized an AI language model to rewrite and present the news or article in a unique format.
USFDA grants VAI classification to Dr Reddy’s R&D centre
The Future of Drug Approval: Embracing the USFDA’s RRA
Unlocking the Potential: Boosting India’s Medical Device Industry
The Urgency of Expiry Dates on Doctors’ Prescriptions
NPPA’s move to Fix Prices on Anti-Diabetic FDCs
Changes in Homoeopathy Drug Regulations
FSSAI: Food Labelling and Display – Chapter-1
Laboratory Waste Management, Types and Its Disposal
How to Become a Skilled Manufacturing Chemist in the Pharma Industry
For informative videos by The Health Master, click on the below YouTube icon:
For informative videos on Medical Store / Pharmacy, click on the below YouTube icon:
For informative videos on the news regarding Pharma / Medical Devices / Cosmetics / Homoeopathy etc., click on the below YouTube icon:
For informative videos on consumer awareness, click on the below YouTube icon:
